One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2019-132004
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 1 |
Affiliation: Augusta University Health, Boston University, University of Kansas Cancer Center, University of Kansas Medical Center, Hospital Mãe de Deus, VIR Biotechnology (United States), The Ohio State University, James Cancer Hospital, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, USC Norris Cancer Hospital, University of Colorado Denver, Fox Chase Cancer Center, Thomas Jefferson University, University of California, San Diego, Hackensack University Medical Center, University of California, Irvine Medical Center, University of California, Irvine, Thomas Jefferson University Hospital
Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
